Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 259

1.

Exploring Differences in the Lives and Well-Being of Sexual and Gender Minority Adults Experiencing Homelessness Relative to Their Cisgender Heterosexual Counterparts.

Schick V, Witte L, Misedah L, Benedict W, Falk K, Brown C, Isbell F.

Health Equity. 2019 Mar 14;3(1):68-72. doi: 10.1089/heq.2018.0068. eCollection 2019.

2.

Time Trends and Predictors of Abnormal Postoperative Body Temperature in Infants Transported to the Intensive Care Unit.

Schroeck H, Lyden AK, Benedict WL, Ramachandran SK.

Anesthesiol Res Pract. 2016;2016:7318137. Epub 2016 Sep 29.

3.

A Phase l Study of a Tumor-targeted Systemic Nanodelivery System, SGT-94, in Genitourinary Cancers.

Siefker-Radtke A, Zhang XQ, Guo CC, Shen Y, Pirollo KF, Sabir S, Leung C, Leong-Wu C, Ling CM, Chang EH, Millikan RE, Benedict WF.

Mol Ther. 2016 Aug;24(8):1484-91. doi: 10.1038/mt.2016.118. Epub 2016 Jun 13.

4.
5.

Use of monitoring levels of soluble forms of cytokeratin 18 in the urine of patients with superficial bladder cancer following intravesical Ad-IFNα/Syn3 treatment in a phase l study.

Benedict WF, Fisher M, Zhang XQ, Yang Z, Munsell MF, Dinney CN.

Cancer Gene Ther. 2014 Mar;21(3):91-4. doi: 10.1038/cgt.2014.1. Epub 2014 Feb 7.

6.

Airway exchange failure and complications with the use of the Cook Airway Exchange Catheter®: a single center cohort study of 1177 patients.

McLean S, Lanam CR, Benedict W, Kirkpatrick N, Kheterpal S, Ramachandran SK.

Anesth Analg. 2013 Dec;117(6):1325-7. doi: 10.1213/ANE.0b013e3182a7cd3d.

PMID:
24257382
7.

Phase I trial of intravesical recombinant adenovirus mediated interferon-α2b formulated in Syn3 for Bacillus Calmette-Guérin failures in nonmuscle invasive bladder cancer.

Dinney CP, Fisher MB, Navai N, O'Donnell MA, Cutler D, Abraham A, Young S, Hutchins B, Caceres M, Kishnani N, Sode G, Cullen C, Zhang G, Grossman HB, Kamat AM, Gonzales M, Kincaid M, Ainslie N, Maneval DC, Wszolek MF, Benedict WF.

J Urol. 2013 Sep;190(3):850-6. doi: 10.1016/j.juro.2013.03.030. Epub 2013 Mar 15.

8.

Detection of bladder cancer using proteomic profiling of urine sediments.

Majewski T, Spiess PE, Bondaruk J, Black P, Clarke C, Benedict W, Dinney CP, Grossman HB, Tang KS, Czerniak B.

PLoS One. 2012;7(8):e42452. doi: 10.1371/journal.pone.0042452. Epub 2012 Aug 3.

9.

Low molecular weight cyclin E is associated with p27-resistant, high-grade, high-stage and invasive bladder cancer.

Akli S, Zhang XQ, Bondaruk J, Tucker SL, Czerniak PB, Benedict WF, Keyomarsi K.

Cell Cycle. 2012 Apr 1;11(7):1468-76. doi: 10.4161/cc.19882. Epub 2012 Apr 1.

10.

Direct cytotoxicity produced by adenoviral-mediated interferon α gene transfer in interferon-resistant cancer cells involves ER stress and caspase 4 activation.

Yang Z, Zhang XQ, Dinney CN, Benedict WF.

Cancer Gene Ther. 2011 Sep;18(9):609-16. doi: 10.1038/cgt.2011.26. Epub 2011 Jun 17.

11.
13.
14.

Early RB94-produced cytotoxicity in cancer cells is independent of caspase activation or 50 kb DNA fragmentation.

Zhou J, Zhang XQ, Ashoori F, McConkey DJ, Knowles MA, Dong L, Benedict WF.

Cancer Gene Ther. 2009 Jan;16(1):13-9. doi: 10.1038/cgt.2008.54. Epub 2008 Jul 25.

15.
16.

Perioperative and long-term operative outcomes after surgery for trigeminal neuralgia: microvascular decompression vs percutaneous balloon ablation.

Jellish WS, Benedict W, Owen K, Anderson D, Fluder E, Shea JF.

Head Face Med. 2008 Jul 2;4:11. doi: 10.1186/1746-160X-4-11.

17.

Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy.

Majewski T, Lee S, Jeong J, Yoon DS, Kram A, Kim MS, Tuziak T, Bondaruk J, Lee S, Park WS, Tang KS, Chung W, Shen L, Ahmed SS, Johnston DA, Grossman HB, Dinney CP, Zhou JH, Harris RA, Snyder C, Filipek S, Narod SA, Watson P, Lynch HT, Gazdar A, Bar-Eli M, Wu XF, McConkey DJ, Baggerly K, Issa JP, Benedict WF, Scherer SE, Czerniak B.

Lab Invest. 2008 Jul;88(7):694-721. doi: 10.1038/labinvest.2008.27. Epub 2008 May 5.

18.

Phosphorylation of Thr18 and Ser20 of p53 in Ad-p53-induced apoptosis.

Nakamizo A, Amano T, Zhang W, Zhang XQ, Ramdas L, Liu TJ, Bekele BN, Shono T, Sasaki T, Benedict WF, Sawaya R, Lang FF.

Neuro Oncol. 2008 Jun;10(3):275-91. doi: 10.1215/15228517-2008-015. Epub 2008 Apr 28.

19.

Tumor-targeting nanocomplex delivery of novel tumor suppressor RB94 chemosensitizes bladder carcinoma cells in vitro and in vivo.

Pirollo KF, Rait A, Zhou Q, Zhang XQ, Zhou J, Kim CS, Benedict WF, Chang EH.

Clin Cancer Res. 2008 Apr 1;14(7):2190-8. doi: 10.1158/1078-0432.CCR-07-1951.

20.

Intraventricular schwannoma in a 15-year-old adolescent: a case report.

Benedict WJ Jr, Brown HG, Sivarajan G, Prabhu VC.

Childs Nerv Syst. 2008 Apr;24(4):529-32. doi: 10.1007/s00381-007-0556-6. Epub 2008 Jan 4. Review.

PMID:
18175126
21.

Forerunner genes contiguous to RB1 contribute to the development of in situ neoplasia.

Lee S, Jeong J, Majewski T, Scherer SE, Kim MS, Tuziak T, Tang KS, Baggerly K, Grossman HB, Zhou JH, Shen L, Bondaruk J, Ahmed SS, Samanta S, Spiess P, Wu X, Filipek S, McConkey D, Bar-Eli M, Issa JP, Benedict WF, Czerniak B.

Proc Natl Acad Sci U S A. 2007 Aug 21;104(34):13732-7. Epub 2007 Aug 16.

22.

Enhancement of intravesical delivery with Syn3 potentiates interferon-alpha2b gene therapy for superficial bladder cancer.

Nagabhushan TL, Maneval DC, Benedict WF, Wen SF, Ihnat PM, Engler H, Connor RJ.

Cytokine Growth Factor Rev. 2007 Oct-Dec;18(5-6):389-94. Epub 2007 Aug 9. Review.

PMID:
17692556
23.

A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses.

Sterman DH, Recio A, Carroll RG, Gillespie CT, Haas A, Vachani A, Kapoor V, Sun J, Hodinka R, Brown JL, Corbley MJ, Parr M, Ho M, Pastan I, Machuzak M, Benedict W, Zhang XQ, Lord EM, Litzky LA, Heitjan DF, June CH, Kaiser LR, Vonderheide RH, Albelda SM, Kanther M.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4456-66. Erratum in: Clin Cancer Res. 2007 Sep 1;13(17):5226. Kanther, Michelle [added].

24.

Management of scalp toxic epidermal necrolysis and cranial osteomyelitis with serratus anterior myocutaneous pedicle flap: a case report.

Levitt MR, Benedict WJ, Barton K, Melian E, Gamelli RL, Vandevender D, Rosseau G, Prabhu VC.

J Burn Care Res. 2007 May-Jun;28(3):524-9.

PMID:
17438486
25.

Adenoviral mediated interferon-alpha 2b gene therapy suppresses the pro-angiogenic effect of vascular endothelial growth factor in superficial bladder cancer.

Adam L, Black PC, Kassouf W, Eve B, McConkey D, Munsell MF, Benedict WF, Dinney CP.

J Urol. 2007 May;177(5):1900-6.

PMID:
17437845
26.

Carotid artery pseudoaneurysm resulting from an injury to the neck by a fouled baseball.

Benedict WJ, Prabhu V, Viola M, Biller J.

J Neurol Sci. 2007 May 15;256(1-2):94-9. Epub 2007 Mar 21.

PMID:
17368675
27.

Combination therapy with IFN-alpha plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells.

Papageorgiou A, Kamat A, Benedict WF, Dinney C, McConkey DJ.

Mol Cancer Ther. 2006 Dec;5(12):3032-41. Erratum in: Mol Cancer Ther. 2009 Feb;8(2):480.

28.

Adenoviral-mediated interferon alpha overcomes resistance to the interferon protein in various cancer types and has marked bystander effects.

Zhang X, Yang Z, Dong L, Papageorgiou A, McConkey DJ, Benedict WF.

Cancer Gene Ther. 2007 Mar;14(3):241-50. Epub 2006 Nov 10.

PMID:
17096027
29.
30.

Evidence for alternative candidate genes near RB1 involved in clonal expansion of in situ urothelial neoplasia.

Kim MS, Jeong J, Majewski T, Kram A, Yoon DS, Zhang RD, Li JZ, Ptaszynski K, Kuang TC, Zhou JH, Sathyanarayana UG, Tuziak T, Johnston DA, Grossman HB, Gazdar AF, Scherer SE, Benedict WF, Czerniak B.

Lab Invest. 2006 Feb;86(2):175-90.

31.

Efficacy of a single intravesical treatment with Ad-IFN/Syn 3 is dependent on dose and urine IFN concentration obtained: implications for clinical investigation.

Tao Z, Connor RJ, Ashoori F, Dinney CP, Munsell M, Philopena JA, Benedict WF.

Cancer Gene Ther. 2006 Feb;13(2):125-30.

PMID:
16082384
32.

Role of tumor necrosis factor-related apoptosis-inducing ligand in interferon-induced apoptosis in human bladder cancer cells.

Papageorgiou A, Lashinger L, Millikan R, Grossman HB, Benedict W, Dinney CP, McConkey DJ.

Cancer Res. 2004 Dec 15;64(24):8973-9.

33.

Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein.

Benedict WF, Tao Z, Kim CS, Zhang X, Zhou JH, Adam L, McConkey DJ, Papageorgiou A, Munsell M, Philopena J, Engler H, Demers W, Maneval DC, Dinney CP, Connor RJ.

Mol Ther. 2004 Sep;10(3):525-32.

34.

Focus on bladder cancer.

Dinney CP, McConkey DJ, Millikan RE, Wu X, Bar-Eli M, Adam L, Kamat AM, Siefker-Radtke AO, Tuziak T, Sabichi AL, Grossman HB, Benedict WF, Czerniak B.

Cancer Cell. 2004 Aug;6(2):111-6. Review. No abstract available.

35.

p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer.

Shariat SF, Tokunaga H, Zhou J, Kim J, Ayala GE, Benedict WF, Lerner SP.

J Clin Oncol. 2004 Mar 15;22(6):1014-24. Epub 2004 Feb 23.

PMID:
14981102
36.

Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy.

Slaton JW, Millikan R, Inoue K, Karashima T, Czerniak B, Shen Y, Yang Y, Benedict WF, Dinney CP.

J Urol. 2004 Feb;171(2 Pt 1):570-4.

PMID:
14713761
37.

Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder.

Shariat SF, Matsumoto K, Kim J, Ayala GE, Zhou JH, Jian W, Benedict WF, Lerner S.

J Urol. 2003 Sep;170(3):985-9.

PMID:
12913755
38.

Noninvasive detection of bladder cancer in an orthotopic murine model with green fluorescence protein cytology.

Tanaka M, Gee JR, De La Cerda J, Rosser CJ, Zhou JH, Benedict WF, Grossman HB.

J Urol. 2003 Sep;170(3):975-8.

PMID:
12913753
39.

Efficient therapeutic gene delivery after systemic administration of a novel polyethylenimine/DNA vector in an orthotopic bladder cancer model.

Sweeney P, Karashima T, Ishikura H, Wiehle S, Yamashita M, Benedict WF, Cristiano RJ, Dinney CP.

Cancer Res. 2003 Jul 15;63(14):4017-20.

40.
41.

Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer.

Yamashita M, Rosser CJ, Zhou JH, Zhang XQ, Connor RJ, Engler H, Maneval DC, Karashima T, Czerniak BA, Dinney CP, Benedict WF.

Cancer Gene Ther. 2002 Aug;9(8):687-91.

42.

Visualizing superficial human bladder cancer cell growth in vivo by green fluorescent protein expression.

Zhou JH, Rosser CJ, Tanaka M, Yang M, Baranov E, Hoffman RM, Benedict WF.

Cancer Gene Ther. 2002 Aug;9(8):681-6.

43.

Gene therapy for superficial bladder cancer.

Rosser CJ, Benedict WF, Dinney CP.

Expert Rev Anticancer Ther. 2001 Dec;1(4):531-9. Review.

PMID:
12113085
44.
45.

Susceptibility of nonpromoter CpG islands to de novo methylation in normal and neoplastic cells.

Nguyen C, Liang G, Nguyen TT, Tsao-Wei D, Groshen S, Lübbert M, Zhou JH, Benedict WF, Jones PA.

J Natl Cancer Inst. 2001 Oct 3;93(19):1465-72.

PMID:
11584062
46.

Correlation of immunohistochemical molecular staging of bladder biopsies and radical cystectomy specimens.

Tokunaga H, Shariat SF, Green AE, Brown RM, Zhou JH, Benedict WF, Lerner SP.

Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):16-22.

PMID:
11516846
47.

P53 in bladder cancer: mechanism of action, prognostic value, and target for therapy.

Slaton JW, Benedict WF, Dinney CP.

Urology. 2001 May;57(5):852-9. Review. No abstract available.

PMID:
11337281
48.

An improved intravesical model using human bladder cancer cell lines to optimize gene and other therapies.

Watanabe T, Shinohara N, Sazawa A, Harabayashi T, Ogiso Y, Koyanagi T, Takiguchi M, Hashimoto A, Kuzumaki N, Yamashita M, Tanaka M, Grossman HB, Benedict WF.

Cancer Gene Ther. 2000 Dec;7(12):1575-80.

49.

Brief rapid pacing depresses contractile function via Ca(2+)/PKC-dependent signaling in cat ventricular myocytes.

Wang YG, Benedict WJ, Hüser J, Samarel AM, Blatter LA, Lipsius SL.

Am J Physiol Heart Circ Physiol. 2001 Jan;280(1):H90-8.

50.

Retinoblastoma protein-initiated cellular growth arrest overcomes the ability of cotransfected wild-type p53 to induce apoptosis.

Shinohara H, Zhou J, Yoshikawa K, Yazumi S, Ko K, Yamaoka Y, Mizukami T, Yoshida T, Akinaga S, Tamaoki T, Motoda H, Benedict WF, Takahashi R.

Br J Cancer. 2000 Oct;83(8):1039-46.

Supplemental Content

Loading ...
Support Center